rapt therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. rapt has discovered and advanced two unique drug candidates, flx475 and rpt193, each targeting c-c motif chemokine receptor 4 (ccr4), for the treatment of cancer and inflammation, respectively. the company is also pursuing a range of targets that are in the discovery stage of development.
Company profile
Ticker
RAPT
Exchange
Website
CEO
Brian Wong
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
FLX Bio, Inc.
SEC CIK
Corporate docs
Subsidiaries
RAPT Therapeutics Australia ...
IRS number
473313701
RAPT stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
7 Mar 24
8-K
Regulation FD Disclosure
22 Feb 24
8-K
Other Events
20 Feb 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 23
8-K
Regulation FD Disclosure
3 Nov 23
EFFECT
Notice of effectiveness
18 Aug 23
424B5
Prospectus supplement for primary offering
17 Aug 23
Latest ownership filings
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
WILLIAM HO
1 Feb 24
4
Rodney KB Young
1 Feb 24
4
Dirk G. Brockstedt
1 Feb 24
4
Brian Russell Wong
1 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 54.14 mm | 54.14 mm | 54.14 mm | 54.14 mm | 54.14 mm | 54.14 mm |
Cash burn (monthly) | (no burn) | (no burn) | 11.31 mm | 9.86 mm | 7.29 mm | 7.68 mm |
Cash used (since last report) | n/a | n/a | 67.70 mm | 59.02 mm | 43.68 mm | 45.98 mm |
Cash remaining | n/a | n/a | -13.57 mm | -4.88 mm | 10.45 mm | 8.16 mm |
Runway (months of cash) | n/a | n/a | -1.2 | -0.5 | 1.4 | 1.1 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 101 |
Opened positions | 6 |
Closed positions | 7 |
Increased positions | 37 |
Reduced positions | 36 |
13F shares | Current |
---|---|
Total value | 575.28 bn |
Total shares | 38.22 mm |
Total puts | 9.60 k |
Total calls | 428.20 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
FMR | 4.50 mm | $74.78 bn |
T. Rowe Price | 3.54 mm | $58.73 bn |
Column | 2.68 mm | $44.55 bn |
BLK Blackrock | 2.32 mm | $38.54 bn |
Vanguard | 2.02 mm | $33.63 bn |
Perceptive Advisors | 1.92 mm | $31.92 bn |
Column Group Ii | 1.60 mm | $17.72 mm |
Deep Track Capital | 1.50 mm | $24.93 bn |
Great Point Partners | 1.46 mm | $24.23 bn |
STT State Street | 1.41 mm | $23.38 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Jan 24 | Ho William | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 24.75 | 75,000 | 1.86 mm | 75,000 |
31 Jan 24 | Rodney KB Young | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 24.75 | 90,000 | 2.23 mm | 90,000 |
31 Jan 24 | Brockstedt Dirk G. | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 24.75 | 75,000 | 1.86 mm | 75,000 |
31 Jan 24 | Brian Russell Wong | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 24.75 | 275,000 | 6.81 mm | 275,000 |
5 Jan 24 | Brockstedt Dirk G. | Common Stock | Sell | Dispose S | No | No | 22.78 | 898 | 20.46 k | 27,820 |
News
JP Morgan Maintains Neutral on RAPT Therapeutics, Lowers Price Target to $13
27 Mar 24
RAPT Therapeutics: Q4 Earnings Insights
7 Mar 24
RAPT Therapeutics Q4 EPS $(0.80) Beats $(0.86) Estimate, Cash Balance of $158.9M as of December 31, 2023
7 Mar 24
RAPT Therapeutics Announces Multiple Late-Breaking Presentations At The Upcoming American Association For Cancer Research Annual Meeting
5 Mar 24
UBS Downgrades RAPT Therapeutics to Neutral, Lowers Price Target to $10
22 Feb 24
Press releases
RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm
11 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
11 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
7 Mar 24
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
7 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
3 Mar 24